Vivo Capital, LLC — 13F Holdings & Portfolio

CIK 1674712 · latest 13F-HR filed 2026-11-13

Vivo Capital, LLC manages $908.7M in 13F-reported U.S. long-equity assets across 50 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are PRAX (8.69%), TRVI (6.67%), ERAS (6.49%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 8 new positions and exited 5; 13 existing positions rose in reported value and 27 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$908.7M

Long-equity book

Holdings
50

Distinct positions

Period
2026-09-30

Filed 2026-11-13

Q/Q Activity
+8 / −5 / ↑13 / ↓27

vs 2026-06-30

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q3 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q2 26 → Q3 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

5 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 51.3%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$6.10B
Discretionary
$6.10B
Employees
62
Accounts
16
Address
192 LYTTON AVENUE
PALO ALTO, CA 94301
Phone
(650) 688-0818
Name Title / Status Ownership Type
AGGARWAL, GAURAV ControlMANAGING PARTNER
since Apr 2024
5–10%Individual
CHANG, MICHAEL, J. ControlMANAGING PARTNER
since Jan 2021
5–10%Individual
ENGLEMAN, EDGAR, GEORGE ControlMANAGING PARTNER
since Jun 2005
10–25%Individual
FU, SHAN, (NMN) ControlMANAGING PARTNER
since Jan 2015
10–25%Individual
KUNG, FRANK, FANG-CHIEN ControlMANAGING PARTNER
since Jun 2005
25–50%Individual
SHEU, CINTHIA, HUI-HSIN ControlPARTNER / CHIEF OPERATING OFFICER
since Apr 2008
Less than 5%Individual
WU, ZHANPING, (NMN) ControlPARTNER / GENERAL COUNSEL / CHIEF COMPLIANCE OFFICER
since Nov 2019
Less than 5%Individual
Ownership & leadership changes · 11 filings with changes since Mar 28, 2012

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 31, 2026 filing
  • No longer listedNIELSEN, JACK, BECH · MANAGING PARTNER · 5–10% · control person · listed since Jan 2021
Mar 31, 2025 filing
  • AddedAGGARWAL, GAURAV · MANAGING PARTNER · 5–10% · control person
Mar 28, 2024 filing
  • No longer listedLU, HONGBO, (NMN) · MANAGING PARTNER · 10–25% · control person · listed since Jan 2021
Jan 29, 2021 filing
  • AddedCHANG, MICHAEL, J. · MANAGING PARTNER · 5–10% · control person
  • AddedLU, HONGBO, (NMN) · MANAGING PARTNER · 10–25% · control person
  • AddedNIELSEN, JACK, BECH · MANAGING PARTNER · 5–10% · control person
  • ChangedENGLEMAN, EDGAR, GEORGE · ownership 25–50% → 10–25%
  • ChangedFU, SHAN, (NMN) · ownership 25–50% → 10–25%
  • ChangedSHEU, CINTHIA, HUI-HSIN · title CHIEF OPERATING OFFICER → PARTNER / CHIEF OPERATING OFFICER
  • ChangedWU, ZHANPING, (NMN) · title GENERAL COUNSEL / CHIEF COMPLIANCE OFFICER → PARTNER / GENERAL COUNSEL / CHIEF COMPLIANCE OFFICER
Sep 9, 2020 filing
  • No longer listedCHA, ALBERT, (NMN) · MANAGING PARTNER · 10–25% · control person · listed since Jun 2005
  • ChangedENGLEMAN, EDGAR, GEORGE · ownership 10–25% → 25–50%
  • ChangedFU, SHAN, (NMN) · ownership 10–25% → 25–50%
Aug 31, 2020 filing
  • No longer listedYU, CHEN, MING · MANAGING PARTNER · 10–25% · control person · listed since Jan 2015
Nov 22, 2019 filing
  • AddedWU, ZHANPING, (NMN) · GENERAL COUNSEL / CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedCHA, ALBERT, (NMN) · title MANAGING MEMBER → MANAGING PARTNER
  • ChangedENGLEMAN, EDGAR, GEORGE · title MANAGING MEMBER → MANAGING PARTNER
  • ChangedKUNG, FRANK, FANG-CHIEN · title MANAGING MEMBER → MANAGING PARTNER
  • ChangedSHEU, CINTHIA, HUI-HSIN · title CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER → CHIEF OPERATING OFFICER
Mar 29, 2019 filing
  • ChangedCHA, ALBERT, (NMN) · ownership 25–50% → 10–25%
  • ChangedENGLEMAN, EDGAR, GEORGE · ownership 25–50% → 10–25%
  • ChangedFU, SHAN, (NMN) · ownership 5–10% → 10–25%
Mar 30, 2018 filing
  • ChangedSHEU, CINTHIA, HUI-HSIN · title CHIEF COMPLIANCE OFFICER AND VP OF FINANCE → CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER
Mar 30, 2016 filing
  • AddedFU, SHAN, (NMN) · MANAGING PARTNER · 5–10% · control person
  • AddedYU, CHEN, MING · MANAGING PARTNER · 10–25% · control person
Older changes (2 more filings)
Mar 28, 2014 filing
  • ChangedSHEU, CINTHIA, HUI-HSIN · title VP FINANCE → CHIEF COMPLIANCE OFFICER AND VP OF FINANCE; now a control person
Mar 28, 2012 filing (earliest on record)
  • ListedCHA, ALBERT, (NMN) · MANAGING MEMBER · 25–50% · control person
  • ListedENGLEMAN, EDGAR, GEORGE · MANAGING MEMBER · 25–50% · control person
  • ListedKUNG, FRANK, FANG-CHIEN · MANAGING MEMBER · 25–50% · control person
  • ListedSHEU, CINTHIA, HUI-HSIN · VP FINANCE · Less than 5%

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Vivo Capital, LLC Holdings (2026-09-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 Praxis Precision Medicines PRAX 74006W207 $79.0M 8.69% 271,116 SH
2 Trevi Therapeutics Inc TRVI 89532M101 $60.6M 6.67% 4,229,683 SH
3 Erasca Inc ERAS 29479A108 $58.9M 6.49% 4,020,619 SH
4 Arrivent BioPharma Inc AVBP 04272N102 $54.1M 5.95% 1,787,104 SH
5 Abivax SA ABVX 00370M103 $41.1M 4.52% 414,899 SH
6 Entera Bio Ltd ENTX M40527109 $35.7M 3.92% 12,254,901 SH
7 Aclaris Therapeutics Inc ACRS 00461U105 $35.2M 3.88% 6,694,637 SH
8 Alto Neuroscience Inc ANRO 02157Q109 $34.7M 3.82% 1,359,915 SH
9 Tango Therapeutics Inc TNGX 87583X109 $34.4M 3.79% 1,379,769 SH
10 Corvus Pharmaceuticals Inc CRVS 221015100 $32.3M 3.56% 2,805,816 SH
11 LB Pharmaceuticals Inc LBRX 50180M108 $30.7M 3.38% 800,000 SH
12 Korsana Biosciences Inc KRSA 23255M303 $28.1M 3.09% 877,020 SH
13 Blossomhill Therapeutics Inc BLSM 095130100 $27.8M 3.06% 1,493,740 SH
14 Faeth Therapeutics Inc FTH 81728A207 $25.1M 2.76% 844,576 SH
15 CAMP4 Therapeutics Corporation CAMP 13463J101 $22.6M 2.48% 5,584,111 SH
16 Achieve Life Science Inc QUIT 004468500 $22.3M 2.45% 2,751,032 SH
17 SAB Biotherapeutics Inc SABS 78397T202 $21.9M 2.41% 6,915,011 SH
18 DBV Technologies SA DBVT 23306J309 $21.7M 2.39% 1,844,758 SH
19 Bright Minds Biosciences Inc DRUG 10919W405 $20.8M 2.29% 417,879 SH
20 Design Therapeutics Inc DSGN 25056L103 $20.3M 2.23% 1,612,903 SH
21 AN2 Therapeutics Inc ANTX 037326105 $16.8M 1.85% 3,153,640 SH
22 Moonlake Immunotherapeutics MLTX 61559X104 $16.4M 1.80% 1,400,000 SH
23 Minerva Neurosciences Inc NERV 603380205 $14.5M 1.59% 4,322,747 SH
24 Odyssey Therapeutics Inc ODTX 67613T104 $12.8M 1.41% 575,000 SH
25 Oric Pharmaceuticals Inc ORIC 68622P109 $12.5M 1.37% 924,392 SH
26 Eupraxia Pharmaceuticals Inc EPRX 29842P105 $12.3M 1.35% 1,350,000 SH
27 Vor Biopharma Inc VOR 929033207 $10.5M 1.16% 550,358 SH
28 Editas Medicine Inc EDIT 28106W103 $9.1M 1.01% 3,555,250 SH
29 Surrozen Inc SRZN 86889P208 $8.4M 0.92% 260,000 SH
30 Dyne Therapeutics Inc DYN 26818M108 $8.3M 0.91% 514,402 SH
31 Aura Biosciences Inc AURA 05153U107 $7.3M 0.81% 1,166,667 SH
32 Cue Biopharma Inc CUE 22978P205 $7.2M 0.80% 280,057 SH
33 Monopar Therapeutics Inc MNPR 61023L207 $7.2M 0.79% 90,500 SH
34 Satellos Bioscience Inc MSLE 80401L803 $6.9M 0.76% 813,666 SH
35 Olema Pharmaceuticals Inc OLMA 68062P106 $5.8M 0.64% 671,843 SH
36 Pepgen Inc PEPG 713317105 $5.6M 0.62% 2,325,000 SH
37 Onkure Therapeutics Inc OKUR 68277Q105 $5.3M 0.58% 1,927,710 SH
38 Attovia Therapeutics Inc ATTO 04987L102 $5.1M 0.57% 300,000 SH
39 ADARx Pharmaceuticals Inc ADRX 00654F105 $5.1M 0.56% 255,158 SH
40 Tenax Therapeutics Inc TENX 88032L605 $4.7M 0.52% 2,500,000 SH
41 Valneva SE VALN 92025Y103 $4.7M 0.52% 763,199 SH
42 Avalo Therapeutics Inc AVTX 05338F306 $4.2M 0.46% 275,000 SH
43 Compass Therapeutics Inc CMPX 20454B104 $3.6M 0.39% 3,423,547 SH
44 Sera Prognostics Inc SERA 81749D107 $3.4M 0.38% 1,650,440 SH
45 Instil Bio Inc TIL 45783C200 $2.1M 0.23% 292,743 SH
46 InMed Pharmaceuticals Inc INM 457637700 $1.1M 0.12% 824,874 SH
47 Bolt Biotherapeutics Inc BOLT 097702203 $266.5K 0.03% 72,414 SH
48 Pasithea Therapeutics Corp KTTA 70261F202 $183.8K 0.02% 372,796 SH
49 Precision Biosciences Inc DTIL 74019P207 $29.3K 0.00% 4,675 SH
50 Jasper Therapeutics Inc JSPR 471871202 $3.7K 0.00% 5,364 SH
Filing History
Period Filed AUM Holdings Accession
2026-09-30 2026-11-13 $908.7M 50 0001213900-26-119459
2026-06-30 2026-08-14 $1.10B 47 0001213900-26-089935
2026-03-31 2026-05-15 $1.20B 45 0001213900-26-057929
2026-03-31 2026-05-20 $1.20B 46 0001213900-26-059247
2025-12-31 2026-02-13 $1.55B 47 0001213900-26-016236
2025-09-30 2025-11-14 $1.24B 47 0001213900-25-110767
Filer Information
Address
192 LYTTON AVENUE
PALO ALTO, CA 94301
Phone
(650) 688-0818
Filing Manager
Vivo Capital, LLC
Palo Alto, CA
Signatory
Zhanping Wu
Chief Compliance Officer